News

Fast track for GSK's Ebola vaccine
Enlarge image

ResearchUKSwitzerlandItaly

Fast track for GSK's Ebola vaccine

29.08.2014 - Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

A candidate Ebola vaccine, co-developed by the US National Institutes of Health (NIH), could be given to healthy volunteers in the UK, Gambia and Mali as early as September, said GSK. This is part of an series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in West Africa. Money for the accelarated human trials comes from an international consortium in response to the Ebola epidemic, which the World Health Organisation recently declared a public health emergency of international concern. A £2.8m (€3.5m) grant from the Wellcome Trust, the Medical Research Council and the UK Department for International Development will allow a team led by Professor Adrian Hill, of the Jenner Institute at the University of Oxford, to start safety tests of the vaccine alongside similar trials in the US run by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

The consortium’s funding will also enable GSK to begin manufacturing up to around 10,000 additional doses of the vaccine at the same time as the initial clinical trials, so that if the trials are successful stocks could then be made available immediately by GSK to the WHO to create an emergency immunisation programme for high-risk communities. Before the vaccine can be rolled out to larger at-risk populations – even on an experimental basis –, safety trials with small groups of healthy volunteers are required to ensure that the vaccine does not cause unforeseen side effects, and that it generates a good immune response to Ebola in humans. Pre-clinical research indicated that the candidate provides promising protection in non-human primates exposed to Ebola without significant adverse effects. "There is an urgent need for a protective Ebola vaccine, and it is important to establish that a vaccine is safe and spurs the immune system to react in a way necessary to protect against infection," said NIAID Director Anthony S. Fauci. The institute is testing this same vaccine in the US, in addition to a related vaccine that is designed to protect against two Ebola species. This collaborative multi-trial approach is supposed to ensure the fastest possible progress to determining the best candidate vaccine approach and delivery.

GSK’s acquired the vaccine candidate last year when they bought Okairos, a Swiss-Italian biotechnology company specialised on genetic vaccines for €247m. After their earlier reluctance, the drug maker is now more optimistic. "[GSK] will do the best we can, along with WHO and our partners, to speed up development and explore ways in which the vaccine could contribute to the control of this or future Ebola outbreaks," said Moncef Slaoui, Chairman of Global R&D and Vaccines at GSK, and added: "Today’s announcement shows how private and public partners can pull together to respond to this critical public health emergency."


© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2014-03/fast-track-for-gsks-ebola-vaccine.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news.html?cHash=84e81f78a2ff57fea5f72d810e48c349&sort=asc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4388.8%
  • CO.DON2.51 EUR213.7%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.53 EUR-67.5%
  • THERAMETRICS0.07 CHF-53.3%

No liability assumed, Date: 31.08.2014